173 related articles for article (PubMed ID: 30278571)
1. The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis.
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Sheen SS
Medicine (Baltimore); 2018 Sep; 97(39):e12588. PubMed ID: 30278571
[TBL] [Abstract][Full Text] [Related]
2. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
3. Combination versus single-agent as palliative chemotherapy for gastric cancer.
Choi JH; Choi YW; Kang SY; Jeong GS; Lee HW; Jeong SH; Park JS; Ahn MS; Sheen SS
BMC Cancer; 2020 Mar; 20(1):167. PubMed ID: 32122320
[TBL] [Abstract][Full Text] [Related]
4. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
5. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis.
Ohnuma H; Sato Y; Onoyama N; Hamaguchi K; Hayasaka N; Sato M; Murase K; Takada K; Miyanishi K; Murakami T; Ito T; Nobuoka T; Takemasa I; Kato J
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2385-2396. PubMed ID: 33534051
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
10. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
12. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.
Fanotto V; Uccello M; Pecora I; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Ferrari L; Bordonaro R; Vivaldi C; Gerratana L; Bozzarelli S; Filippi R; Bilancia D; Russano M; Aprile G
Oncologist; 2017 Dec; 22(12):1463-1469. PubMed ID: 28860412
[TBL] [Abstract][Full Text] [Related]
14. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Koo DH; Ryu MH; Ryoo BY; Seo J; Lee MY; Chang HM; Lee JL; Lee SS; Kim TW; Kang YK
Gastric Cancer; 2015 Apr; 18(2):346-53. PubMed ID: 24832201
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.
Fanotto V; Cordio S; Pasquini G; Fontanella C; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Torri V; Aprile G
Gastric Cancer; 2017 Sep; 20(5):825-833. PubMed ID: 28028664
[TBL] [Abstract][Full Text] [Related]
16. The role of surgical resection before palliative chemotherapy in advanced gastric cancer.
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Son SY; Hur H; Han SU; Sheen SS
Sci Rep; 2019 Mar; 9(1):4136. PubMed ID: 30858457
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
18. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Oncology; 2010; 79(5-6):363-9. PubMed ID: 21430405
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
